To make things easier, leave this box checked On shared devices, we recommend that you disconnect from Euroquity when you are done
Email

You will receive an email to define a new password

Location

Select your country

and your language

Hi ,

Welcome to your personnel profile page! Fill in your information in order to become more visible to organizations that interest you.

% completed

%

medal 1
This profile is validated by 1 label.

Company

Bio Optical Detection

Bio Optical Detection_logo
25
EQ SCORE

The EQ Score shows the company's activity and appeal on the platform: profile completeness, news, likes, follows, membership in one or more labels or communities, number of members in its network, etc.

Bio Optical Detection has developed a fully functional allergy diagnostic device (TRL 6), presented at Europe’s largest medical industry trade fair. Currently, we are working to commercialize the device, with the market launch planned for 2022.

Mejorada del Campo, Madrid, Spain

Send a message

English

Bio Optical Detection

English

Bio Optical Detection S.L. (biod) was initially conceived by scientists from the Optics, Photonics and Bio-Photonics research group based at the Centre of Biomedical Technology, Technical University of Madrid. After its founding in 2010, the company focused primarily on R&D activities in collaboration with public and private institutions (e.g., the then Spanish Ministry of Economics and Competitiveness, which funded ATAPoC, a point-of-care allergy diagnostic project (Grant...

See more

Bio Optical Detection S.L. (biod) was initially conceived by scientists from the Optics, Photonics and Bio-Photonics research group based at the Centre of Biomedical Technology, Technical University of Madrid. After its founding in 2010, the company focused primarily on R&D activities in collaboration with public and private institutions (e.g., the then Spanish Ministry of Economics and Competitiveness, which funded ATAPoC, a point-of-care allergy diagnostic project (Grant RTC-2015-3273-1), and Horus Pharma, which funded development of our first technology demonstrator through an engineering contract).


In 2017, a new shareholder joined biod, providing €130,000 of seed money, and the company pivoted towards bringing its own solution to the market. Since autumn 2017, it has been the lead commercial partner within the project AllerScreening (a research and innovation action supported by the EU Horizon 2020 programme, Grant 768641). To further support its growth plans, biod has begun offering screening services for pharmaceutical companies, generating its first revenues not derived from R&D projects.


In November 2019, biod presented a fully functional allergy diagnostic device (TRL 6) at MEDICA 2019 in Düsseldorf, Europe’s largest medical industry trade fair. Currently, we are working to commercialise the device, with the market launch planned for 2022.

Certifications

InvestHorizon - Accelerated
The InvestHorizon Accelerated label is for selected deep tech companies from the accelerator programme to facilitate series A funding.  This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential. InvestHorizon is a programme financed by the European Commission in association with Eureka to foster investment readiness.
454 Entities

Communities

InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
2672 Members

Our history

Start in Founding

  • Founding

    After winning 2nd prize of innovation challenge at Technical University Madrid.

  • First major projects grant

    Under the EU-FP7 umbrella. The project was called "EnviGuard" and it had a focus on aquaculture.

  • MVP

    First private project. Developed with Bioftalmik and Horus Pharma with a focus on ophtalmology.

  • First patent

    Exclusive patent granted for technology initially developed at UPM.

  • EU H2020 project

    Commercial lead partner within EU H2020 project called AllerScreening, focused on food allergies.

to be continued ...